Assay sensitivity and study features in neuropathic pain trials: An ACTTION meta-Analysis

Neurology

Volumn 81, Issue 1, 2013, Pages 67-75

  Dworkin, Robert H ^a   Turk, Dennis C ^b   Peirce Sandner, Sarah ^a   He, Hua ^a   McDermott, Michael P ^a   Farrar, John T ^c   Katz, Nathaniel P ^d   Lin, Allison H ^e   Rappaport, Bob A ^e   Rowbotham, Michael C ^f  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d TUFTS UNIVERSITY   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; PLACEBO;

AGE; ARTICLE; CAUCASIAN; DATA BASE; DISEASE ASSOCIATION; EFFECT SIZE; HUMAN; META ANALYSIS; NEUROPATHIC PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS;

AGE FACTORS; CLINICAL TRIALS AS TOPIC; HUMANS; NEURALGIA; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84881250015     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318297ee69     Document Type: Article

References (40)

1. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004;63:959-965.
2. Dworkin RH, OConnor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-251.
3. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. Eur J Neurol 2010;17:1113-1123.
4. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76:1758-1765.
5. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150:573-581.
6. Pfizer protocol A0081071. A randomized double-blind, placebo-controlled, parallel-group, multi-center trial of pregabalin versus placebo in the treatment of neuropathic pain associated with diabetic peripheral neuropathy, 2007 [online]. Available at: http://www.clinicalstudyresults.org/drugdetails/? Drug-name-id=203&indication-keyword=neuropathy&sort=c. company-name&page=2&drug-id=3972. Accessed January 30, 2011.
7. Pfizer. Pfizer reports top-line results from phase 3 trial of Lyrica (pregabalin) capsules CV in patients with inadequately treated painful diabetic peripheral neuropathy, 2012 [online]. Available at: http://www.pfizer.com/news/ press-releases/pfizer-press-release.jsp?guid=20120504005287en&source= RSS-2011&page=1. Accessed August 27, 2012.
8. TOlle T, Freynhagen R, Versavel M, Trostmann U, Young JP, Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008;12:203-213.
9. International Conference on Harmonisation. E10: choice of control groups and related issues in clinical trials, 2001 [online]. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm125912.pdf. Accessed August 27, 2012.
10. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005;65:S32-S49.
11. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology 2008;70:263-272.
12. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012; 153:1148-1158.
13. Dworkin RH, Turk DC, Katz NP, et al. Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain 2011;152(suppl 3):S107-S15.
14. Rappaport BA, Cerny I, Sanhai WR. ACTION on the prevention of chronic pain after surgery. Anesthesiology 2010;112:509-510.
15. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain 2010;150:12-16.
16. Dworkin RH, Peirce-Sandner S, Turk DC, et al. Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database. Osteoarthritis Cartilage 2011;19:483-492. Corrigendum: Osteoarthritis Cartilage 2011;19:919.
17. HaanpM, Attal N, BackonjaM, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152:14-27.
18. Curtin F, Altman DG, Elbourne D. Meta-Analysis combining parallel and cross-over clinical trials. I: continuous outcomes. Stat Med 2002;21:2131-2144.
19. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons; 2008.
20. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-Analyses can provide accurate results. J Clin Epidemiol 2006;59:7-10.
21. Reichenbach S, Sterchi R, Scherer M, et al. Meta-Analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007;146:580-590.
22. Normand SL. Meta-Analysis: formulating, evaluating, combining, and reporting. Stat Med 1999;18:321-359.
23. Whitehead A. Meta-Analysis of Controlled Clinical Trials. Chichester: John Wiley & Sons; 2002.
24. Hedges LV, Tipton E, Johnson MC. Robust variance estimation in meta-regression with dependent effect size estimates. Res Synth Method 2010;1:39-65.
25. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to Meta-Analysis. Chichester: John Wiley & Sons; 2009.
26. Sterne JA, Egger M. Funnel plots for detecting bias in meta-Analysis: guidelines on choice of axis. J Clin Epidemiol 2001;54:1046-1055.
27. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV-Associated neuropathy. Neurology 2000;54:2115-2119.
28. Levendoglu F, Ogn CO, Ozerbil O, Ogn TC, Ugurlu H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 2004;29: 743-751.
29. Quessy SN, Rowbotham MC. Placebo response in neuropathic pain trials. Pain 2008;138:479-483.
30. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996:17:1-12.
31. Ziegler D, Pritchett YL, Wang F, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care 2007;30: 664-669.
32. Nesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-Analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515.
33. Bafeta A, Dechartres A, Trinquart L, Yavchitz A, Boutron I, Ravaud P. Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. BMJ 2012;344:e813.
34. Institute of Medicine. Transforming Clinical Research in the United States: Challenges and Opportunities. Washington, DC: National Academies Press; 2010 [online]. Available at: http://www.nap.edu/catalog.php?record-id=12900. Accessed August 27, 2012.
35. Huser W, Bartram-Wunn E, Bartram C, Reinecke H, TOlle T. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy: magnitude and patient-related factors. Pain 2011;152:1709-1717.
36. Irizarry MC, Webb DJ, Ali Z, et al. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain 2009;25:469-476.
37. Rowbotham MC. The case for publishing negative trials. Pain 2009;146:225-226.
38. Greene K, Dworkin RH, Rowbotham MC. A snapshot and scorecard for analgesic clinical trials for chronic pain: the RReACT database. Pain 2012;153:1794-1797.
39. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI. Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 2002;21:371-387.
40. Harris RE, Williams DA, McLean SA, et al. Characterization and consequences of pain variability in individuals with fibromyalgia. Arthritis Rheum 2005;52: 3670-3674.